131I治疗Graves'病后发生甲低与TGA,TMA及TRAb的关系

目的：从甲状腺自身免疫方面探讨^131Ⅰ治疗甲亢的效果及甲低发生的因素。方法：选择^131Ⅰ治疗的88例Graves’病甲亢患者随访3年，分为第1组(TGA、TMA、TRAb均阳性)和第二组(TGA、TMA阴性，TRAb阳性)。采用x^2分析自身抗体水平与甲低发生的关系。结果：1组甲低发生率为31．4％，2组为3．8％，1组明显高于2组，差异有显著性。结论：TGA、TMA和TRAb水平与确定^131Ⅰ剂量及甲低的发生关系密切。认为TGA、TMA水平高的患者应酌情减少^131Ⅰ用量。

Serum Thyroid Auto-antibody Contents in GD Patients Developing Hypothyroidism After 131I Treatment

Objective To explore the auto-immune factors predisposing to developing, hypothyroidism after 131 I treatment in patients with Graves' disease (GD). Methods Eighty-eight GD patients treated with 131 I were followed for three years. These patients were of two groups: Group A (n=35), serum TGA,TMA,TRAb all positive before treatmnet; Group B (n=53) serum TGA, TMA negative but TRAb positive. Results In Group A, 31.40% (n=11) of all the patients were hypothyroid three years after treatment. The result was much better in Group B, with only 3.8% (n=2) being hypothyroid. The difference was significant. Conclusion GD patients with positive TGA, TMA were liable to develop hypothyroidism after 131 I treatment. Those patients should be treated with lesser amount of the drug accordinly.